Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 25Kidney Neoplasms 6Neoplasms 5Neoplasm Metastasis 4Clear-cell metastatic renal cell carcinoma 4Uterine Cervical Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Melanoma 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphatic Metastasis 1Lung Neoplasms 1Kidney Diseases 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

Specimen Handling 4lutetium Lu 177 dotatate 3gallium Ga 68 dotatate 3Magnetic Resonance Spectroscopy 3olaparib 2cabozantinib 2belzutifan 2Temozolomide 2Nivolumab 2Fluorodeoxyglucose F18 2Biopsy 2talazoparib 1spartalizumab 1pembrolizumab 1lanreotide 1guadecitabine 1fludarabine phosphate 1copper dotatate CU-64 1atezolizumab 1ONC206 1Lutetium-177 1Lutetium 1Ipilimumab 1Interleukin-13 1Genetic Testing 1Everolimus 1Cyclophosphamide 1Contrast Media 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma × Axitinib × 1 year × Clear all
NCT03839498 2026-03-02

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Columbia University

Phase 2 Active not recruiting
6 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡